Longitudinal changes in risk status in pulmonary arterial hypertension. (10th December 2020)

• Record Type: Journal Article
• Authors: Bouzina, Habib; Rådegran, Göran; Butler, Oisin; Hesselstrand, Roger; Hjalmarsson, Clara; Holl, Katsiaryna; Jansson, Kjell; Klok, Rogier; Söderberg, Stefan; Kjellström, Barbro
• Is Part Of: ESC heart failure. Volume 8:Number 1(2021)
• Page Start: 680
• Page End: 690
• Publication Date: 2020-12-10
• Subjects: Pulmonary arterial hypertension -- Risk Assessment -- Treatment -- Longitudinal analysis; Heart failure -- Periodicals; 616.129005
• DOI: 10.1002/ehf2.13162
• Languages: English
• ISSNs: 2055-5822

Abstract

Abstract: Aims: Low‐risk status in pulmonary arterial hypertension (PAH) predicts better survival. The present study aimed to describe changes in risk status and treatment approaches over multiple clinical assessments in PAH, taking age and comorbidity burden into consideration. Methods and results: The study included incident patients from the Swedish PAH registry, diagnosed with PAH in 2008–2019. Group A ( n = 340) were ≤75 years old with <3 comorbidities. Group B ( n = 163) were >75 years old with ≥3 comorbidities. Assessments occurred at baseline, first‐year (Y1) and third‐year (Y3) follow‐ups. The study used an explorative and descriptive approach. Group A: median age was 65 years, 70% were female, and 46% had no comorbidities at baseline. Baseline risk assessment yielded low (23%), intermediate (66%), and high risk (11%). Among patients at low, intermediate, or high risk at baseline, 51%, 18%, and 13%, respectively, were at low risk at Y3. At baseline, monotherapy was the most common therapy among low (68%) and intermediate groups (60%), while dual therapy was the most common among high risk (69%). In patients assessed as low, intermediate, or high risk at Y1, 66%, 12%, and 0% were at low risk at Y3, respectively. Of patients at intermediate or high risk at Y1, 35% received monotherapy and 13% received triple therapy. In low‐risk patients at Y1, monotherapy (40%) and dual therapy (43%) were evenly distributed. Group B: median age was 77 years, 50% were female, and 44% had ≥3 comorbidities at baseline. At baseline, 8% were at low, 80% at intermediate, and 12% at high risk. Monotherapy was the most common therapy (62%) in Group B at baseline. Few patients maintained or reached low risk at follow‐ups. Conclusions: Most patients with PAH did not meet low‐risk criteria during the 3 year follow‐up. The first year from diagnosis seems important in defining the longitudinal risk status.